Form 8-K - Current report:
SEC Accession No. 0001213900-24-005727
Filing Date
2024-01-23
Accepted
2024-01-23 16:05:27
Documents
14
Period of Report
2024-01-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192042-8k_citius.htm   iXBRL 8-K 29794
2 PRESS RELEASE, DATED JANUARY 23, 2024 ea192042ex99-1_citius.htm EX-99.1 14848
3 GRAPHIC ex99-1_001.jpg GRAPHIC 13932
  Complete submission text file 0001213900-24-005727.txt   242825

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20240123.xsd EX-101.SCH 3027
5 XBRL LABEL FILE ctxr-20240123_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20240123_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea192042-8k_citius_htm.xml XML 3309
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 24552517
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)